文献速递颈动脉与弓上血管

颈动脉支架置入术后闭合型与开放型支架再狭窄及再干预率比较

Comparison of restenosis and reintervention rates in closed cell stents compared to open cell stents after carotid artery stenting.
PubMed 文献 · J Vasc Surg · 2025-04-01

该回顾性研究纳入2015至2024年本院246例颈动脉支架置入患者,比较闭合型支架(CCS,118例)与开放型支架(OCS,128例)的结局。两组30天及中期随访卒中、心肌梗死、死亡复合结局无差异,但CCS组再狭窄(13.6% vs 1.6%)和再干预(11% vs 0%)更高,多因素分析显示CCS再狭窄风险增高(校正HR 10.28)。

要点

  • CCS组再狭窄率13.6%,OCS组1.6%,差异有统计学意义(P < .001)。
  • CCS组再干预率11%,OCS组0%,差异有统计学意义(P < .001)。
  • 30天及中期随访卒中、心肌梗死、死亡复合结局两组无差异。

核心结论

  • CCS与OCS在短期和中期随访中卒中、心肌梗死或死亡方面无差异。
  • 中期随访中CCS组再狭窄和再干预率更高,且在症状性和无症状性亚组中均持续存在。

研究设计与样本

  • 回顾性研究,纳入2015年至2024年本院所有经颈动脉和经股动脉入路的颈动脉支架置入术患者。
  • 共246例患者,其中OCS组128例(Enroute支架76例、Protégé支架34例、Precise支架15例、Acculink支架3例),CCS组118例(Wallstent支架118例)。
  • 按症状状态进行亚组分析。

主要发现

  • 总体队列基线特征中,体重指数CCS组28.57 ± 6.19 kg/m2 vs OCS组29.79 ± 5.98 kg/m2(P = .018),症状状态CCS组78例(66.1%)vs OCS组34例(26.6%)(P < .001)。
  • 症状性患者亚组中,接受CCS的糖尿病患者比例33.3%,高于OCS的14.7%(P = .043)。
  • 总体队列随访期间心肌梗死OCS组4.7% vs CCS组0%(P = .03),但该差异在症状性和无症状性亚组分析中未持续存在。
  • 再狭窄CCS组16例(13.6%)vs OCS组2例(1.6%)(P < .001),再干预CCS组13例(11%)vs OCS组0例(0%)(P < .001)。
  • 多因素分析显示CCS再狭窄风险增高(校正风险比10.28;95%置信区间2.25-47.09;P = .003)。

关键数值与推荐

  • 再狭窄定义及再干预指征原文未报告。
  • 随访时间为14.5 ± 15.1个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to compare short- and mid-term outcomes after carotid artery stenting (CAS) related to stent configuration. METHODS: This is a retrospective study of all CAS including transcarotid and transfemoral approaches, performed at our institution from 2015 to 2024. Groups were identified according to the stent used at the index procedure by open-cell stents (OCS) and closed-cell stents (CCS). Subgroup analysis by symptomatic status was also performed. Stroke, myocardial infarction (MI), and death were analyzed, including those occurring within 30 days of procedure and on last follow-up (14.5 ± 15.1 months). Restenosis and need for reintervention were also assessed. RESULTS: Two hundred forty-six patients were included in our study cohort, with 128 OCS (Enroute stent [Silkroad Medical], 76; Protégé stent [Medtronic], 34; Precise stent [Cordis], 15; Acculink stent [Abbott], 3), and 118 CCS (Wallstent [Boston Scientific], 118). Baseline characteristics and comorbidities of the overall cohort showed differences in body mass index (CCS: 28.57 ± 6.19 kg/m2, OCS: 29.79 ± 5.98 kg/m2; P = .018) and symptomatic status (CCS: 78; 66.1%, OCS: 34; 26.6%; P < .001). In subgroup analysis within symptomatic and asymptomatic patients, these differences did not persist. Of note, in symptomatic patients, a higher rate of diabetics received CCS (33.3%) compared with OCS (14.7%; P = .043). Composite outcomes of stroke, MI, and death were no different at 30 days and on mid-term follow-up (14.5 ± 15.1 months). Only MI at follow-up in the overall cohort was significantly higher in the OCS group (4.7%) compared with CCS (0%; P = .03); however, this difference did not persist in subgroup analysis among symptomatic and asymptomatic patients. Restenosis (CCS: 16; 13.6%, OCS: 2; 1.6%; P < .001) and reinterventions (CCS: 13; 11%, OCS: 0; 0%; P < .001) were higher in the CCS group. Furthermore, this difference persisted for both outcomes in symptomatic and asymptomatic subgroup analysis. Multivariate analysis showed increased risk for restenosis in CCS (adjusted hazard ratio, 10.28; 95% confidence interval, 2.25-47.09; P = .003). CONCLUSIONS: No difference in short- and mid-term outcomes was present in either CCS or OCS regarding stroke, MI, or death. On mid-term follow-up, CCS patients had a higher rate of restenosis and reintervention, and this difference persisted in both symptomatic and asymptomatic subgroups.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Polania-Sandoval C, Meschia JF, Huang J, et al. Comparison of restenosis and reintervention rates in closed cell stents compared to open cell stents after carotid artery stenting. J Vasc Surg. 2025. PMID: 40180162. doi:10.1016/j.jvs.2025.03.199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。